Amalgamated Bank Sells 18,476 Shares of Boston Scientific Co. (NYSE:BSX)

Amalgamated Bank decreased its holdings in Boston Scientific Co. (NYSE:BSX - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 356,921 shares of the medical equipment provider's stock after selling 18,476 shares during the quarter. Amalgamated Bank's holdings in Boston Scientific were worth $20,634,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Aveo Capital Partners LLC lifted its position in shares of Boston Scientific by 1.3% during the fourth quarter. Aveo Capital Partners LLC now owns 12,841 shares of the medical equipment provider's stock worth $742,000 after purchasing an additional 171 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in Boston Scientific by 7.7% during the 4th quarter. First Horizon Advisors Inc. now owns 4,970 shares of the medical equipment provider's stock worth $287,000 after buying an additional 356 shares in the last quarter. West Family Investments Inc. boosted its position in Boston Scientific by 12.2% in the 4th quarter. West Family Investments Inc. now owns 4,354 shares of the medical equipment provider's stock valued at $252,000 after buying an additional 473 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Boston Scientific by 0.6% in the 4th quarter. Fisher Asset Management LLC now owns 3,993,388 shares of the medical equipment provider's stock valued at $230,858,000 after buying an additional 22,946 shares during the period. Finally, First Trust Direct Indexing L.P. raised its position in shares of Boston Scientific by 6.7% during the fourth quarter. First Trust Direct Indexing L.P. now owns 35,024 shares of the medical equipment provider's stock worth $2,025,000 after acquiring an additional 2,187 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on BSX. StockNews.com lowered Boston Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, March 16th. Barclays boosted their price target on shares of Boston Scientific from $70.00 to $78.00 and gave the stock an "overweight" rating in a research note on Friday, April 26th. Robert W. Baird raised their price objective on shares of Boston Scientific from $79.00 to $84.00 and gave the company an "outperform" rating in a research note on Thursday, April 25th. Citigroup lifted their target price on shares of Boston Scientific from $79.00 to $85.00 and gave the stock a "buy" rating in a report on Thursday, April 25th. Finally, UBS Group increased their price target on Boston Scientific from $74.00 to $90.00 and gave the company a "buy" rating in a research note on Thursday, April 25th. Three investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $75.09.

Boston Scientific Stock Up 1.2 %

BSX stock traded up $0.83 during midday trading on Friday, hitting $72.86. The company's stock had a trading volume of 7,452,079 shares, compared to its average volume of 6,661,660. The company's fifty day moving average price is $68.30 and its 200 day moving average price is $61.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.32 and a quick ratio of 0.82. Boston Scientific Co. has a twelve month low of $48.35 and a twelve month high of $74.39. The stock has a market capitalization of $109.29 billion, a P/E ratio of 61.23, a PEG ratio of 2.48 and a beta of 0.77.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to the consensus estimate of $3.59 billion. Boston Scientific had a return on equity of 16.63% and a net margin of 12.06%. During the same quarter in the previous year, the business earned $0.45 earnings per share. As a group, equities research analysts predict that Boston Scientific Co. will post 2.32 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total transaction of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The sale was disclosed in a filing with the SEC, which is available through this link. In related news, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the sale, the executive vice president now owns 50,638 shares in the company, valued at approximately $3,509,213.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the transaction, the executive vice president now directly owns 56,508 shares of the company's stock, valued at $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold a total of 78,384 shares of company stock worth $5,395,560 in the last 90 days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.